{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:13:25Z","timestamp":1788455605880,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005061","name":"Innogenetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005062","name":"Fujirebio Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jmii.2022.06.002","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T11:56:07Z","timestamp":1656762967000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-4036","authenticated-orcid":false,"given":"Sylvia M.","family":"Brakenhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"de Knegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo J.H.","family":"van Campenhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek A.","family":"van der Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem P.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"van B\u00f6mmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-6241","authenticated-orcid":false,"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jmii.2022.06.002_bib1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Biological basis for functional cure of chronic hepatitis B","volume":"75","author":"Martinez","year":"2019","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.jmii.2022.06.002_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jmii.2022.06.002_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.jmii.2022.06.002_bib4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jmii.2022.06.002_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jmii.2022.06.002_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cis859","article-title":"Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response","volume":"56","author":"Sonneveld","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.002_bib7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","author":"Giersch","year":"2017","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jmii.2022.06.002_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/infdis\/jiy270","article-title":"Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis B","volume":"218","author":"van Bommel","year":"2018","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jmii.2022.06.002_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"9454","key":"10.1016\/j.jmii.2022.06.002_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jmii.2022.06.002_bib11","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/ajg.2010.186","article-title":"A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B","volume":"105","author":"Rijckborst","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jmii.2022.06.002_bib12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study)","volume":"61","author":"Brouwer","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jmii.2022.06.002_bib13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.002_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciaa013","article-title":"Hepatitis B virus RNA as early predictor for response to PEGylated interferon alfa in HBeAg negative chronic hepatitis B","volume":"72","author":"Farag","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jmii.2022.06.002_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van Bommel","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jmii.2022.06.002_bib16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.29872","article-title":"Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment","volume":"68","author":"van Campenhout","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jmii.2022.06.002_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/jvh.13117","article-title":"Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B","volume":"26","author":"van Campenhout","year":"2019","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.jmii.2022.06.002_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.002_bib19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hep.31525","article-title":"Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat","volume":"73","author":"Liaw","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jmii.2022.06.002_bib20","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/jgh.13377","article-title":"Flares during long-term entecavir therapy in chronic hepatitis B","volume":"31","author":"Chi","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jmii.2022.06.002_bib21","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/gut.2004.062208","article-title":"Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy","volume":"54","author":"Flink","year":"2005","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.jmii.2022.06.002_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.jmii.2022.06.002_bib23","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.14560","article-title":"Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes","volume":"47","author":"Van Hees","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jmii.2022.06.002_bib24","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jmii.2022.06.002_bib25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2020.06.097","article-title":"Nucleic acid polymer therapy for hbv - strong hbsag decline but many unanswered questions","volume":"160","author":"Sonneveld","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jmii.2022.06.002_bib26","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jmii.2022.06.002_bib27","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.002_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S2468-1253(19)30325-5","article-title":"Core inhibitor therapy for chronic hepatitis B","volume":"5","author":"Sonneveld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:30:09Z","timestamp":1761658209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118222000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1684118222000937"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2022.06.002","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2022.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}